<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913495</url>
  </required_header>
  <id_info>
    <org_study_id>16D.542</org_study_id>
    <nct_id>NCT02913495</nct_id>
  </id_info>
  <brief_title>Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth</brief_title>
  <acronym>VIP</acronym>
  <official_title>Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the two suggested therapies for prevention of
      recurrent preterm birth (PTB) in women with a prior spontaneous preterm birth, vaginal and
      intramuscular progesterone to determine whether vaginal progesterone is superior to
      intramuscular progesterone in the prevention of recurrent preterm birth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm birth is one of the leading causes of neonatal morbidity and mortality. One of the
      greatest predictors of preterm birth is a history of prior spontaneous preterm birth.
      Presently 17 hydroxyprogesterone caproate (intramuscular) is the only FDA approved product
      for the prevention of recurrent preterm birth, however recent studies suggest that vaginal
      progesterone may be used for this purpose, and may even be superior. The American College of
      Obstetrics and Gynecology does not specify the optimal route of progesterone administration
      for the prevention of recurrent preterm birth. It is our intention to compare vaginal and
      intramuscular progesterone to see if one is superior.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm birth &lt;37 weeks</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
    <description>Incidence of gestational age of delivery less than 37 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age of delivery</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth &lt;34 weeks and &lt;28 weeks</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second trimester cervical length &lt;25mm</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
    <description>Delivery mode- vaginal, cesarean, operative vaginal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal mortality</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 minute Apgar score</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admission</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
    <description>(respiratory distress syndrome, grade III or IV intraventricular hemorrhage, culture proven sepsis, neonatal enterocolitis, and perinatal mortality up to 28 days of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality up to 28 days of life</measure>
    <time_frame>up to 10 months (4 weeks after delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication side effects</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with medication (5 point Likert scale)</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
    <description>Vaginal progesterone:
Overall adherence: #days used/#days of treatment x 100
Non-adherent: ≥4 days between doses
Intramuscular progesterone:
Overall adherence: #weeks used/#weeks of treatment x 100
Non-adherent: ≥10 days between doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned subgroup analysis for the outcome preterm birth &lt;37 weeks, &lt;34 weeks, &lt;28 weeks</measure>
    <time_frame>up to 9 months (delivery)</time_frame>
    <description>Planned subgroup analysis for the primary outcome as well as the secondary outcomes of preterm birth &lt;34 weeks and &lt;28 weeks of patients with a cervical length &lt;25mm versus ≥25mm, history-indicated cerclage versus not, BMI &gt;=35 versus BMI&lt;35 and for those started on progesterone 16-20 weeks versus 20-24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Progesterone</intervention_name>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <other_name>micronized progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Progesterone</intervention_name>
    <arm_group_label>Intramuscular Progesterone</arm_group_label>
    <other_name>Makena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with singleton pregnancies

          -  ≥18 years old

          -  Estimated gestational age less than 24 0/7 weeks

          -  Prior spontaneous preterm birth of a singleton pregnancy between 16 0/7-36 6/7 weeks.

          -  Patients are also required provide consent, demonstrate an understanding of the
             purpose of the study, and agree to the study protocol.

        Exclusion Criteria:

          -  History of an adverse reaction to progesterone;

          -  A contraindication to progesterone treatment;

          -  Placenta previa or accreta;

          -  Major fetal anomaly diagnosed on ultrasound or known chromosomal disorder;

          -  Multifetal gestation;

          -  Preterm labor, premature rupture of membranes, or clinical chorioamnionitis, at the
             time of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupsa C Boelig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University Hospital; Sidney Kimmel Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupsa C Boelig, MD</last_name>
    <email>rupsa.boelig@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Gimovsky, MD</last_name>
      <email>agimovsky@mfa.gwu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina Schoen, MD</last_name>
      <email>Corina.SchoenMD@baystatehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupsa C Boelig, MD</last_name>
      <email>rupsa.boelig@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012 Oct;120(4):964-73.</citation>
    <PMID>22996126</PMID>
  </reference>
  <reference>
    <citation>Saccone G, Khalifeh A, Elimian A, Bahrami E, Chaman-Ara K, Bahrami MA, Berghella V. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2017 Mar;49(3):315-321. doi: 10.1002/uog.17245. Epub 2017 Feb 6. Review.</citation>
    <PMID>27546354</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Prevention of preterm birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Results will be available, individual participant data may not be</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

